Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.
about
Remote magnetic targeting of iron oxide nanoparticles for cardiovascular diagnosis and therapeutic drug delivery: where are we now?Biogenic Fabrication of Iron/Iron Oxide Nanoparticles and Their ApplicationGlomerular capillary hemorrhage induced in rats by diagnostic ultrasound with gas-body contrast agent produces intratubular obstruction.Dynamic contrast-enhanced magnetic resonance imaging of tumor-induced lymph flow.The risks of inappropriateness in cardiac imagingMRI contrast agents: basic chemistry and safety.National Institutes of Health Perspective on Reports of Gadolinium Deposition in the Brain.Normal saline as a natural intravascular contrast agent for dynamic perfusion-weighted MRI of the brain: Proof of concept at 1.5T.Influence of Ecto-nucleoside triphosphate diphosphohydrolase activity on Trypanosoma cruzi infectivity and virulenceSynthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imagingMacromolecules, dendrimers, and nanomaterials in magnetic resonance imaging: the interplay between size, function, and pharmacokinetics.Gain of a 500-fold sensitivity on an intravital MR contrast agent based on an endohedral gadolinium-cluster-fullerene-conjugate: a new chance in cancer diagnosticsSingle-dose gadobutrol in comparison with single-dose gadobenate dimeglumine for magnetic resonance imaging of chronic myocardial infarction at 3 T.N-acetylcysteine protects rats with chronic renal failure from gadolinium-chelate nephrotoxicity.Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer.Synergy between surface and core entrapped metals in a mixed manganese-gadolinium nanocolloid affords safer MR imaging of sparse biomarkers.Magnetic nanoparticles: preparation, physical properties, and applications in biomedicine.Gadolinium-based contrast agents: did we miss something in the last 25 years?Minimizing risk of nephrogenic systemic fibrosis in cardiovascular magnetic resonanceMRI study of subconjunctival and intravitreal injections.Fragmentation behavior of DOTA complexes under different activation conditions.Atherosclerotic neovasculature MR imaging with mixed manganese-gadolinium nanocolloids in hyperlipidemic rabbitsMRI of the basement membrane using charged nanoparticles as contrast agentsA peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI.Pathophysiology of gadolinium-associated systemic fibrosisStem cell labeling for magnetic resonance imaging.Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 ExaminationsNovel contrast mechanisms at 3 Tesla and 7 TeslaEvaluation of CLT1-(Gd-DTPA) for Cancer MR Molecular Imaging in a Mouse Breast Cancer Model.Magnetic quantum dots for multimodal imaging.Nanotechnology in the diagnosis of atherosclerotic disease.Gadolinium and nephrogenic systemic fibrosis: an update.Risk of nephrogenic systemic fibrosis is low in patients with chronic liver disease exposed to gadolinium-based contrast agents.Phospholipid micelle encapsulated gadolinium oxide nanoparticles for imaging and gene delivery.Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update.Self-assembled polymeric nanoparticles as new, smart contrast agents for cancer early detection using magnetic resonance imaging.Cellular internalization and morphological analysis after intravenous injection of a highly hydrophilic octahedral rhenium cluster complex - a new promising X-ray contrast agent.Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids.A platform for specific delivery of lanthanide-scandium mixed-metal cluster fullerenes into target cells.Ligand-directed nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets
P2860
Q26739877-422A1255-DDFB-4E42-A0C8-3C8CF83A261CQ28069790-871707E7-14EA-4D62-B989-A00CE7F60F64Q30481781-995BE390-00E2-4FF3-BCE4-65C53ED26E61Q30482388-B3546DBD-D81D-4702-AB2F-9F57260A1E4DQ30488883-83AE9672-E451-481B-AC13-67CD0CB6F6B8Q30574482-D2F9F972-9190-41F5-92A9-784C8ADEA1E7Q31039888-7E90158D-4F95-40B2-9086-8F4CAE8D51F0Q31086314-FC5CDAFD-F577-4E2F-A1A8-F28606F27518Q33414099-2814229E-63BE-4F51-8AA8-1E4E39BD5552Q33768662-106954D1-0181-4F10-991A-EDBD039D8B06Q33847006-139D9650-EFDD-4DE1-A16A-38CD183ACB05Q33894429-F6E83063-C29C-4F6A-AA58-B8B6DCE6CCC5Q34337600-278B9AFB-3B43-4791-8112-C22C69181D81Q34344717-870B51C7-AB4E-4558-9623-9E36C59BB341Q35236565-9532A575-E177-4319-B873-234DE5F66D4EQ35317271-7C17EC0D-DEB9-416B-AF82-93BE0302AFB9Q35854293-FBB85EF1-38B7-4BFC-B278-1E6705FD9E34Q35878856-7F87493C-0DAA-490B-8985-5A19C45157EEQ36130156-60A620A0-D712-4033-B3AA-968CF2EBC454Q36212580-E40D7881-3C32-4C94-8EF1-B93E89C8806AQ36358790-1E5DF264-0CC3-4233-BFAF-4EE93716915BQ36483514-FC0CAEB5-C6E8-4528-ACA7-D57BFA826362Q36924700-6E64EC99-0D9C-4EC1-985E-4B75DE1DB382Q37118318-792A4AA2-3159-4352-BEC0-5ACA519C7196Q37139482-14980A91-21B6-460B-9412-70CED266638CQ37157684-880E89DD-5756-42A8-AF92-BA9224A49D2CQ37250096-A0419515-EE42-45AF-A8A1-B059D77FC389Q37292519-95990A4E-4988-490F-A1BF-F6BE6BDC85ACQ37490152-9579837E-6F3C-4AC1-945B-162D72F31852Q37668366-043F57C9-A318-42CE-A6D9-3777A5DAB900Q38089761-28C1229E-F587-4D32-8BEE-09516D28C928Q38154533-7236D028-757A-4F5B-83A2-6819391E67D4Q38210490-D7130831-C630-4E34-B78E-C6658C0A6D78Q38657765-51C44006-186F-44C1-A136-2ECF25DCCAD5Q38667169-2CA91B5A-4E4C-417D-A17D-768EC732A4B9Q38922451-E0CF9AC7-5661-454B-9D1F-63524790E575Q40636025-76E612F6-70B0-46A3-9EB2-DC0A04ECA33AQ41883594-D978615C-8526-41F0-B2B6-F344BB32D938Q41951086-A3EA794F-9603-4487-9A72-C3BDECDA59DDQ41976159-3E1E78C6-151C-4311-94A6-99C95A8C007D
P2860
Biochemical safety profiles of gadolinium-based extracellular contrast agents and nephrogenic systemic fibrosis.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Biochemical safety profiles of ...... nephrogenic systemic fibrosis.
@en
type
label
Biochemical safety profiles of ...... nephrogenic systemic fibrosis.
@en
prefLabel
Biochemical safety profiles of ...... nephrogenic systemic fibrosis.
@en
P2860
P356
P1476
Biochemical safety profiles of ...... nephrogenic systemic fibrosis.
@en
P2093
Frank J Rybicki
Hale Ersoy
P2860
P304
P356
10.1002/JMRI.21135
P577
2007-11-01T00:00:00Z